Enliven Therapeutics, Inc. (ELVN) — Total Liabilities
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2025 | $16.57M | +4.1% |
| 2024 | $15.91M | -38.7% |
| 2023 | $25.96M | +150.3% |
| 2022 | $10.37M | +36.2% |
| 2021 | $7.62M | +18.9% |
| 2020 | $6.41M | +46.2% |
| 2019 | $4.38M | — |
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2025 | $16.57M | +4.1% |
| 2024 | $15.91M | -38.7% |
| 2023 | $25.96M | +150.3% |
| 2022 | $10.37M | +36.2% |
| 2021 | $7.62M | +18.9% |
| 2020 | $6.41M | +46.2% |
| 2019 | $4.38M | — |